Myelodysplastic syndromes (DC 7725) | VA Rating Tool
| Diagnostic Code | 7725 |
|---|---|
| Category | The Hemic and Lymphatic Systems |
| Subcategory | The Hematologic and Lymphatic Systems |
| Also Known As | Myelodysplastic syndromes |
| CFR Section | 4.117 |
Next Steps for This Condition
Rating Criteria
| Rating | Criteria |
|---|---|
| 100% | Note (2): A 100 percent evaluation shall be assigned as of the date of hospital admission for peripheral blood or bone marrow stem cell transplant, or during the period of treatment with chemotherapy, and shall continue with a mandatory VA examination six months following hospital discharge or, in the case of chemotherapy treatment, six months after completion of treatment. Any reduction in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no recurrence, residuals will be rated under the appropriate diagnostic codes |
| 100% | Requiring peripheral blood or bone marrow stem cell transplant; or requiring chemotherapy |
| 60% | Requiring 4 or more blood or platelet transfusions per 12-month period; or infections requiring hospitalization 3 or more times per 12-month period |
| 30% | Requiring at least 1 but no more than 3 blood or platelet transfusions per 12-month period; infections requiring hospitalization at least 1 but no more than 2 times per 12-month period; or requiring biologic therapy on an ongoing basis or erythropoiesis stimulating agent (ESA) for 12 weeks or less per 12-month period |